Alvotech (ALVO)
Alvotech (ALVO) Stock Price, Analysis & Data
No data available
| Bid | 2.7 |
| Market Cap | 1.38B |
| Revenue (ttm) | 562.04M |
| Net Income (ttm) | -80.73M |
| Beta | 0.18 |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | n/a |
| Forward PE | 15.64 |
| P/B (ttm) | -4.52 |
| P/S (ttm) | 2.46 |
| Earnings Date | Aug 19, 2026 |
| Ask | 4.74 |
| Volume | 559,659 |
| Avg. Volume (20D) | 850,911 |
| Open | 3.98 |
| Previous Close | 4.01 |
| Day's Range | 3.84 - 4.14 |
| 52-Week Range | 2.94 - 9.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing s...
Financial Performance
In 2025, Alvotech's revenue was 586.32M, an increase of 19.74% compared to the previous year's 489.68M. Earnings were 27.92M, a decrease of -112.04%.
Financial StatementsAnalyst Forecast
According to undefined analyst ratings, the average rating for ALVO stock is "undefined". The 12-month stock price forecast is null, which is downside of 0% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
